



*The Nutrition Society Summer Meeting was held at King's College, London on 10–12 July 2017*

## Conference on 'Improving nutrition in metropolitan areas' Postgraduate Symposium

# 25(OH)D<sub>3</sub>-enriched or fortified foods are more efficient at tackling inadequate vitamin D status than vitamin D<sub>3</sub>

Jing Guo<sup>1\*</sup>, Julie A. Lovegrove<sup>2</sup> and D. Ian Givens<sup>1</sup>

<sup>1</sup>*Institute for Food, Nutrition and Health, University of Reading, Reading RG6 6AR, UK*

<sup>2</sup>*Hugh Sinclair Unit of Human Nutrition, Department of Food & Nutritional Sciences, University of Reading, Reading RG6 6AP, UK*

The ability to synthesise sufficient vitamin D through sunlight in human subjects can be limited. Thus, diet has become an important contributor to vitamin D intake and status; however, there are only a few foods (e.g. egg yolk, oily fish) naturally rich in vitamin D. Therefore, vitamin D-enriched foods via supplementing the animals' diet with vitamin D or vitamin D fortification of foods have been proposed as strategies to increase vitamin D intake. Evidence that cholecalciferol (vitamin D<sub>3</sub>) and calcifediol (25(OH)D<sub>3</sub>) content of eggs, fish and milk increased in response to vitamin D<sub>3</sub> supplementation of hens, fish or cows' diets was identified when vitamin D-enrichment studies were reviewed. However, evidence from supplementation studies with hens showed only dietary 25(OH)D<sub>3</sub>, not vitamin D<sub>3</sub> supplementation, resulted in a pronounced increase of 25(OH)D<sub>3</sub> in the eggs. Furthermore, evidence from randomised controlled trials indicated that a 25(OH)D<sub>3</sub> oral supplement could be absorbed faster and more efficiently raise serum 25(OH)D concentration compared with vitamin D<sub>3</sub> supplementation. Moreover, evidence showed the relative effectiveness of increasing vitamin D status using 25(OH)D<sub>3</sub> varied between 3·13 and 7·14 times that of vitamin D<sub>3</sub>, probably due to the different characteristics of the investigated subjects or study design. Therefore, vitamin D-enrichment or fortified foods using 25(OH)D<sub>3</sub> would appear to have advantages over vitamin D<sub>3</sub>. Further well-controlled studies are needed to assess the effects of 25(OH)D<sub>3</sub> enriched or fortified foods in the general population and clinical patients.

### Enrichment: Fortification: 25(OH)D<sub>3</sub>: Vitamin D<sub>3</sub>: Vitamin D deficiency

Vitamin D is usually synthesised in skin that is exposed to UV radiation, which has led to the term 'sunshine vitamin'<sup>(1)</sup>. Traditionally, the primary role of vitamin D is related to calcium absorption and bone health. Children and adults with vitamin D deficiency have an increased risk of developing rickets or osteomalacia<sup>(2)</sup>. Recently, a resurgence of childhood rickets has highlighted the need for adequate vitamin D status in many parts of the

world<sup>(3–5)</sup>. Furthermore, mounting evidence from epidemiological studies indicates that vitamin D status is inversely associated with the risk of CVD, cancers and diabetes<sup>(1,6)</sup>, although there is some uncertainty about what defines an adequate vitamin D status<sup>(7)</sup>.

Vitamin D deficiency is prevalent and is considered a serious issue throughout the world<sup>(8–10)</sup>, even in sunnier climates such as Australia and New Zealand<sup>(11)</sup>.

**Abbreviations:** 25(OH)D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub>; RCT, randomised controlled trial.

\*Corresponding author: Dr J. Guo, email [sarah.guo@reading.ac.uk](mailto:sarah.guo@reading.ac.uk)



Recently, the Scientific Advisory Committee on Nutrition<sup>(7)</sup> reported that in the UK, 22–24 % of adults aged 19–64 years, and 17–24 % of those ≥65 years were vitamin D deficient (plasma 25-hydroxyvitamin D<sub>3</sub> (25(OH)D<sub>3</sub>) <25 nmol/l). There are several factors that have contributed to the low vitamin D status commonly seen today, such as lifestyle changes (increased indoor lifestyle, sun screens use) and human characteristics (e.g. ageing, clothing, increased obesity, low-fat diet trend)<sup>(12)</sup>. Therefore, foods that contribute to vitamin D intake have become more important than before. However, there are only a few foods naturally rich in vitamin D, such as oily fish and egg yolks<sup>(13)</sup>.

The aim of this review is first to critically evaluate the existing evidence on whether the vitamin D content of animal-derived foods can be increased by feeding cholecalciferol (vitamin D<sub>3</sub>) and/or calcifediol (25(OH)D<sub>3</sub>) supplements to laying hens, fish and cows. Second, the present review summarises evidence from the human randomised controlled trials (RCT), which include the effects of 25(OH)D<sub>3</sub> supplementation on increasing serum/plasma 25(OH)D<sub>3</sub> concentration.

### Vitamin D absorption, synthesis and metabolism

Generally, the term vitamin D refers to both vitamin D<sub>2</sub> and vitamin D<sub>3</sub>. Vitamin D<sub>2</sub> is produced by fungi, while vitamin D<sub>3</sub> is produced by human subjects and animals<sup>(14)</sup>. Human subjects usually synthesise vitamin D<sub>3</sub> in the skin<sup>(15)</sup> where 7-dehydrocholesterol in the epidermis is converted to pre-vitamin D<sub>3</sub> when skin is exposed to sunlight. Then, pre-vitamin D<sub>3</sub> undergoes a temperature-dependent isomerisation to vitamin D<sub>3</sub> over a period of approximately 3 d<sup>(6)</sup>. Vitamin D (vitamin D<sub>2</sub> or vitamin D<sub>3</sub>) can also be obtained from the diet<sup>(15)</sup> and it is absorbed with long-chain TAG in the small intestine<sup>(16)</sup>. It is then incorporated into chylomicrons and transported in lymph to the blood and into the general circulation<sup>(17)</sup>.

After entering the circulation, there are two hydroxylation reactions to convert vitamin D to the biologically active form<sup>(6)</sup>. The first hydroxylation reaction is in the liver where vitamin D is hydroxylated to 25(OH)D by the vitamin D-25-hydroxylase enzyme. The second hydroxylation reaction is in the kidney where 25(OH)D is converted to 1,25(OH)<sub>2</sub>D by 25-hydroxyvitamin D-1 $\alpha$ -hydroxylase<sup>(6)</sup>, and the 1,25(OH)<sub>2</sub>D metabolite is the biologically active form of vitamin D<sup>(18)</sup>.

### Foods of animal origin as dietary sources of vitamin D

Vitamin D content of vitamin D-enriched foods can differ considerably between food retailers. One US retail study analysed the vitamin D content of egg yolks collected from twelve individual retail supermarkets across the country and reported a broad range of vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> concentrations of 9.7–18 and 4.3–13.2  $\mu$ g/kg, respectively<sup>(19)</sup>. In addition, our recent UK retail study<sup>(20)</sup> showed vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub>

concentrations of eggs were significantly different depending on the egg production systems. Egg yolks produced by birds kept in indoor systems had much lower concentrations (40.2 (SE 3.1)  $\mu$ g/kg) of vitamin D<sub>3</sub> than the egg yolks produced from outdoor systems (57.2 (SE 3.2)  $\mu$ g/kg), while 25(OH)D<sub>3</sub> concentrations of the eggs were higher in organic eggs only. Similarly, the vitamin D contents of fish have been shown to vary according to the production systems. The study of Lu *et al.*<sup>(21)</sup> indicated the vitamin D<sub>3</sub> content of wild salmon to be three times higher than that of farmed salmon; however, the 25(OH)D<sub>3</sub> content of the salmon was not measured. In addition, other studies<sup>(22,23)</sup> have shown the 25(OH)D<sub>3</sub> content of several species of marine and freshwater fish to be <0.02  $\mu$ g/100 g. Therefore, foods generally regarded as rich sources of vitamin D may not be sustainable vitamin D contributors for the general population, due to variability in vitamin D content, which in turn may be influenced by production systems or different species (genotype). Furthermore, the National Diet and Nutrition Survey of the UK<sup>(24)</sup> reported that the average daily intake of vitamin D for adults was 3.1  $\mu$ g for men and 2.6  $\mu$ g for women, which is much lower than the UK vitamin D reference nutrition intake of 10  $\mu$ g/d<sup>(7)</sup>. Therefore, vitamin D-enriched or fortified foods are needed to ensure an adequate vitamin D intake for the general population.

### Enrichment of animal-derived foods as dietary sources of vitamin D

#### *Vitamin D-enriched eggs*

In general, there are two main methods to enrich the vitamin D content of eggs: increased sunlight exposure and vitamin D supplementation of the birds' diet. Because hens can synthesise vitamin D from natural sunlight exposure, free-range egg production system may be an inexpensive way to increase their vitamin D content. A study by Kuhn *et al.* assigned laying hens to a free-range treatment or an indoor treatment for over 4 weeks and found that eggs from the free-range group, which were exposed to sunlight, had significantly higher vitamin D<sub>3</sub> content (mean 14.3  $\mu$ g/100 g DM) than eggs from the indoor group (mean 3.8  $\mu$ g/100 g DM)<sup>(25)</sup>. Furthermore, there are several studies which have shown that the vitamin D<sub>3</sub> content of eggs can be enhanced by feeding vitamin D<sub>3</sub> supplements to the hens (Table 1)<sup>(26–32)</sup>. The results of all studies revealed that egg yolk vitamin D<sub>3</sub> concentration was efficiently increased by vitamin D<sub>3</sub> dietary supplementation. The study of Yao *et al.* showed a linear dose–response relationship existed between vitamin D<sub>3</sub> dietary supplementation and vitamin D<sub>3</sub> concentrations of egg yolks<sup>(30)</sup>. Moreover, as 25(OH)D<sub>3</sub> is a metabolite of vitamin D<sub>3</sub>, the 25(OH)D<sub>3</sub> content in eggs can also be enhanced by supplementing the birds' diet with vitamin D<sub>3</sub>. However, the response in 25(OH)D<sub>3</sub> content of egg yolk is much less than that of vitamin D<sub>3</sub>. Browning and Cowieson<sup>(31)</sup> showed that a 4-fold increase in vitamin D<sub>3</sub>, and a 2-fold increase in 25(OH)D<sub>3</sub> in egg yolk resulted from a 4-fold increase in the vitamin D<sub>3</sub>

**Table 1.** Summary of enrichment studies investigating the impact of adding vitamin D to the diet of laying hens on the vitamin D content of egg yolks

References	Vitamin D supplement ( $\mu\text{g}/\text{kg}$ )		Feeding duration (weeks)	Vitamin D concentration of egg yolk ( $\mu\text{g}/100\text{ g}$ )	
	Vitamin D <sub>3</sub>	25(OH)D <sub>3</sub>		Vitamin D <sub>3</sub>	25(OH)D <sub>3</sub>
Mattila <i>et al.</i> <sup>(26)</sup>	26.6	–	6	1.4	0.5
	62.4	–	6	3.5	0.9
	216.0	–	6	22.0	1.5
Mattila <i>et al.</i> <sup>(27)</sup>	280.0	–	4	30.0	1.9
Mattila <i>et al.</i> <sup>(28)</sup>	62.5	–	4	3.8	–
	150.0	–	4	13.6	–
Browning and Cowieson <sup>(31)</sup>	375.0	–	4	33.7	–
	62.5	–	9	6.5	1.6
	125.0	–	9	10.5	2.1
Yao <i>et al.</i> <sup>(30)</sup>	250.0	–	9	26.2	3.0
	55.0	–	3	3.0	–
	242.5	–	3	21.6	–
Browning and Cowieson <sup>(31)</sup>	430.0	–	3	41.0	–
	617.5	–	3	60.3	–
	2555.0	–	3	870.4	–
	62.5	0	9	6.5	1.6
	62.5	34.5	9	6.0	3.3
	62.5	69.0	9	4.9	4.5
	125.0	0	9	10.5	2.1
125.0	34.5	9	7.4	4.5	
Browning and Cowieson <sup>(31)</sup>	125.0	69.0	9	8.1	5.8
	250.0	0	9	26.2	3.0
	250.0	34.5	9	23.6	3.7
	250.0	69.0	9	30.9	8.1
	250.0	69.0	9	30.9	8.1
Mattila <i>et al.</i> <sup>(29)</sup>	–	55.0	6	$\leq 0.2$	2.1
	–	122.0	6	$\leq 0.2$	4.3
Duffy <i>et al.</i> <sup>(32)</sup>	37.5	–	4	1.0*	1.9*
	75.0	–	4	2.0*	1.9*
	37.5	37.5	4	1.3*	3.6*
	–	75.0	4	0.7*	4.4*

25(OH)D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub>.

\* Vitamin D content per egg.

in the diet (62.5–250  $\mu\text{g}/\text{kg}$ ). Similarly, evidence from another study showed that the vitamin D<sub>3</sub> in egg yolk was increased approximately 7-fold as a result of feeding a diet with a 3.5-fold higher vitamin D<sub>3</sub> content (from 62.4 to 216  $\mu\text{g}/\text{kg}$ ), while the corresponding increase in 25(OH)D<sub>3</sub> content was only about 1.5-fold<sup>(26)</sup>.

There are only a few studies<sup>(29,31,32)</sup> examining the effect of feeding birds with diets supplemented with 25(OH)D<sub>3</sub>. In the EU, 25(OH)D<sub>3</sub> has only recently been authorised for addition to poultry diets, and the maximum content of the vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> combination for laying hens is 80  $\mu\text{g}/\text{kg}$ <sup>(33,34)</sup>. It is of note that most of vitamin D supplementation studies<sup>(27–31)</sup>, summarised in Table 1, had higher vitamin D doses than the EU diet limit<sup>(33)</sup>, thus, the potential for increasing vitamin D in eggs by adding vitamin D to the diet of laying hens is limited by EU regulations. Browning and Cowieson<sup>(31)</sup> and Duffy *et al.*<sup>(32)</sup> both showed an addition of 25(OH)D<sub>3</sub> to the vitamin D<sub>3</sub> supplement resulted in the elevation of the 25(OH)D<sub>3</sub> content of the egg yolk, but there was no significant increase in the vitamin D<sub>3</sub> content of the egg yolk. Other studies investigated dietary supplementation with 25(OH)D<sub>3</sub><sup>(29,32)</sup>, and showed that

only egg yolk 25(OH)D<sub>3</sub> was increased, but not vitamin D<sub>3</sub>. Therefore, we speculate that 25(OH)D<sub>3</sub> in the diet can be absorbed directly by laying hens without transfer to vitamin D<sub>3</sub> in the circulation.

#### Vitamin D-enriched fish

There are very few studies on enriching the vitamin D content of fish (Table 2)<sup>(35–38)</sup>. Mattila *et al.* fed rainbow trout with different doses of vitamin D<sub>3</sub> supplements up to 539  $\mu\text{g}/\text{kg}$ , but no significant differences in the vitamin D<sub>3</sub> content of the fish fillet were observed<sup>(37)</sup>. In contrast, the study of Horvli *et al.* with Atlantic salmon showed a dose–response relationship between the vitamin D<sub>3</sub> in the diet up to 28.68 mg/kg and vitamin D<sub>3</sub> in the fish meat<sup>(35)</sup>. Similar high vitamin D<sub>3</sub> supplementation doses were reported in another two studies<sup>(36,38)</sup>, which also showed that elevated vitamin D<sub>3</sub> content of the fish liver or whole fish had been achieved by supplemental vitamin D<sub>3</sub> in the diet. However, 25(OH)D<sub>3</sub> contents of the enriched fish were not measured in these studies<sup>(35–38)</sup>, and the lack of evidence on the effects by feeding fish with 25(OH)D<sub>3</sub> on the vitamin D content of the

**Table 2.** Summary of enrichment studies investigating the impact of vitamin D supplemental fish feeding on vitamin D content of fish

References	Vitamin D <sub>3</sub> supplement (µg/kg)	Feeding duration (weeks)	Vitamin D <sub>3</sub> of fish (µg/100 g)
Horvli <i>et al.</i> <sup>(35)</sup>	40	11	1 (fillet)
	2210	11	21 (fillet)
	28 680	11	210 (fillet)
Vielma <i>et al.</i> <sup>(36)</sup>	62.5	12	1 (liver)
	6250	12	73 (liver)
	62 500	12	6900 (liver)
Mattila <i>et al.</i> <sup>(37)</sup>	89	16	6–15 (fish fillet)
	174	16	6–10 (fish fillet)
	539	16	7–16 (fish fillet)
Graff <i>et al.</i> <sup>(38)</sup>	200	9	≤25 (whole fish)*
	5000	9	80 (whole fish)*
	57 000	9	650 (whole fish)*

\* Estimated from graph.

fish warrants further research. Again, supplement doses of the listed studies<sup>(35–38)</sup> in Table 2 were over the EU diet limit for farmed fish of 75 µg/kg<sup>(33)</sup>, which will limit application in the market.

#### Vitamin D-enriched milk

A few studies have investigated the longer term effect of supplemental vitamin D<sub>3</sub> on the vitamin D content of the milk; the summary of these studies is presented in Table 3<sup>(39–42)</sup>. Hollis *et al.* showed a 10-fold enhancement of vitamin D<sub>3</sub> intake from 100 to 1000 µg/d resulted in a 7.5-fold increased vitamin D<sub>3</sub> concentration of the milk and a 2-fold increase in 25(OH)D<sub>3</sub><sup>(39)</sup>. Moreover, McDermott *et al.* compared three different doses of vitamin D<sub>3</sub> with a control diet, and showed an increased concentration of vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> in the milk<sup>(41)</sup>. However, the relationship between increasing dietary vitamin D<sub>3</sub> doses and milk vitamin D<sub>3</sub> or 25(OH)D<sub>3</sub> concentrations were not linear. Furthermore, the study of Weiss *et al.* investigated the effect of feeding 450 µg/d vitamin D<sub>3</sub> to pre-calving cows for 13 d which resulted in concentrations of vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> in the milk ranging from 0.33–0.45 to 0.36–1.02 µg/l, respectively<sup>(42)</sup>. In addition, the study included a diet treatment of 6 mg vitamin D<sub>3</sub> with a cation–anion difference of –138 mEq/kg daily for 13 d; the concentrations of 25(OH)D<sub>3</sub> in the milk were increased but the treatment effect disappeared after 28 d. Therefore, evidence from the limited number of studies<sup>(39–42)</sup> demonstrated that milk vitamin D concentrations can be increased by feeding dairy cows with vitamin D supplements. However, it is of note that the highest milk vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> concentrations were 0.47 and 3.69 µg/l, respectively (Table 3), which for one typical milk serving of 200 ml only contributes 0.09 and 0.74 µg vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub>, respectively, well below the current UK vitamin D reference nutrition intake of 10 µg/d<sup>(7)</sup>. Furthermore, the doses of vitamin D in those studies<sup>(41,42)</sup> were much higher than the maximum allowed vitamin D content

in EU (0.01 mg/kg diet at 880 g DM/kg approximately equivalent to 2.27 mg/d)<sup>(34)</sup>, which imposes an even greater restriction on the possibility of increasing vitamin D in milk by adding vitamin D supplements in the diet of dairy cows.

#### Evidence from human dietary intervention studies with vitamin D-enriched animal-derived foods

Despite numerous animal-based vitamin D-enrichment studies on vitamin D in eggs, fish and milk, there are few RCT on the effect of consuming vitamin D-enriched foods on the vitamin D status of the consumer. To our knowledge, only one recent study has investigated the weekly effect of consuming seven vitamin D<sub>3</sub> or seven 25(OH)D<sub>3</sub>-enriched eggs on vitamin D status compared with commercial eggs of ≤2 egg/week<sup>(43)</sup>. After 8 weeks follow-up in winter, the results showed that while the serum 25(OH)D of the subjects who consumed commercial eggs decreased from a baseline of 41 (SD 14.1) nmol/l to 35 (SD 11.4) nmol/l, the serum 25(OH)D of subjects who consumed vitamin D<sub>3</sub>-enriched eggs or 25(OH)D<sub>3</sub>-enriched eggs was maintained. The serum 25(OH)D concentrations of subjects who consumed vitamin D<sub>3</sub>- or 25(OH)D<sub>3</sub>-enriched eggs were 50 (SD 21.4) nmol/l and 49 (SD 16.5) nmol/l, respectively. However, there was no significant difference between vitamin D<sub>3</sub>- and 25(OH)D<sub>3</sub>-enriched egg consumption on serum 25(OH)D concentrations.

Although there are a limited number of human dietary intervention studies on vitamin D-enriched foods, the study of Mattila *et al.*<sup>(29)</sup> demonstrated that the effect of foods enriched with either vitamin D<sub>3</sub> or 25(OH)D<sub>3</sub> on human vitamin D status depended on their relative effectiveness of raising serum or plasma 25(OH)D concentrations. A previous study<sup>(44)</sup> indicated that there was no consensus on the relative effectiveness of 25(OH)D<sub>3</sub> compared with vitamin D<sub>3</sub> for raising human serum or plasma 25(OH)D<sub>3</sub> concentrations. Furthermore, UK food composition tables<sup>(45)</sup> indicate that there is no certainty on the relative potency of 25(OH)D<sub>3</sub> compared with vitamin D<sub>3</sub>, although it was assumed that 25(OH)D<sub>3</sub> had a potency of five times that of vitamin D<sub>3</sub> for calculating the total vitamin D of foods<sup>(45)</sup>.

#### Human intervention studies on the relative effects of calcifediol and cholecalciferol supplementation on vitamin D status

##### Heterogeneity of intervention studies

Eleven RCT that investigated the effects of 25(OH)D<sub>3</sub> relative to vitamin D<sub>3</sub> were identified<sup>(46–56)</sup> (Table 4). Nine studies administered 25(OH)D<sub>3</sub> supplementation only, except two studies which provided a combination supplement of 25(OH)D<sub>3</sub> and calcium<sup>(46,49)</sup>. Five of the eleven studies<sup>(47,49–52)</sup> supplemented 25(OH)D<sub>3</sub> to generally healthy subjects, whereas the other six studies<sup>(46,48,53–56)</sup> supplemented 25(OH)D<sub>3</sub> to clinical patients. Most studies reported the serum or plasma

**Table 3.** Summary of enrichment studies investigating the impact of vitamin D supplementation to the diet of dairy cows on vitamin D content of milk

References	Supplements to diet ( $\mu\text{g}/\text{d}$ )			Vitamin D concentration of milk ( $\mu\text{g}/\text{l}$ )		
	Vitamin D <sub>3</sub>	25(OH)D <sub>3</sub>	Feeding duration	Vitamin D <sub>3</sub>	25(OH)D <sub>3</sub>	1,25(OH) <sub>2</sub> D <sub>3</sub>
Hollis <i>et al.</i> <sup>(39)</sup>	100	–	NA	0.04	0.37	0.01
	1000	–	NA	0.32	0.68	0.004
Reeve <i>et al.</i> <sup>(40)</sup>	375	–	30 d	0.28	0.15	0.01
Mcdermott <i>et al.</i> <sup>(41)</sup>	0	–	14 weeks	0.08	0.25	0.10
	250	–	14 weeks	0.20	0.43	0.03
	1250	–	14 weeks	0.15	0.75	0.13
	6250	–	14 weeks	0.33	0.93	0.10
Weiss <i>et al.</i> <sup>(42)</sup>	450	–	13 d before calving	0.33–0.47	0.36–1.02	–
	–	DCAD + 6000	13 d before calving	–	0.61–3.69	–

25(OH)D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub>; 1,25(OH)<sub>2</sub>D<sub>3</sub>, 1,25 dihydroxyvitamin D<sub>3</sub>; DCAD, dietary cation–anion difference of  $-138 \text{ mEq}/\text{kg}$ .

25(OH)D concentration at both the beginning and end of the treatment, except one study<sup>(55)</sup>, which only reported the 25(OH)D concentration at the end of the treatment. In terms of the vitamin D status measurement, most studies measured total 25(OH)D concentration, except two studies<sup>(49,52)</sup>, which measured 25(OH)D<sub>3</sub>. For the characteristics of the investigated subjects, five studies included both men and women<sup>(46,48,51,53,55)</sup>, while the other studies only included men or women. In addition, most studies reported the age and BMI of the subjects, except two studies<sup>(46,48)</sup> that did not report the BMI range.

#### *Acute pharmacokinetic action of cholecalciferol and calcifediol*

An early study provided meals with single doses of 25(OH)D<sub>3</sub> of 1.5, 5 or 10  $\mu\text{g}/\text{kg}$  body weight to generally healthy subjects and showed that the peak serum 25(OH)D<sub>3</sub> concentration was reached within 4–8 h after ingestion<sup>(57)</sup>. A later study by Jetter *et al.* compared the pharmacokinetic absorption of vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> by providing a single dose of 20  $\mu\text{g}$  vitamin D<sub>3</sub> or 20  $\mu\text{g}$  25(OH)D<sub>3</sub> to postmenopausal women<sup>(52)</sup>. The time to reach maximum plasma 25(OH)D<sub>3</sub> concentration was 22 and 11 h for vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub>, respectively. In addition, the peak concentration of plasma 25(OH)D<sub>3</sub> (44 nmol/l) from 25(OH)D<sub>3</sub> supplementation was higher than vitamin D<sub>3</sub> supplementation (35 nmol/l), although they were not significantly different. This study further compared the effect of a higher single dose of 140  $\mu\text{g}$  vitamin D<sub>3</sub> and 140  $\mu\text{g}$  25(OH)D<sub>3</sub> with the time to reach peak plasma 25(OH)D<sub>3</sub> being 21 and 4.8 h for vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub> supplementation, respectively<sup>(52)</sup>. In addition, the maximum plasma concentration of 25(OH)D<sub>3</sub> for 25(OH)D<sub>3</sub> treatment (100 nmol/l) was significantly higher than for vitamin D<sub>3</sub> treatment (44 nmol/l). These results suggest that 25(OH)D<sub>3</sub> was absorbed more quickly than vitamin D<sub>3</sub> possibly because 25(OH)D<sub>3</sub> has higher solubility in aqueous media than vitamin D<sub>3</sub> due to its more polar chemical structure<sup>(58)</sup>. Furthermore, as this metabolite of vitamin D<sub>3</sub> is produced in the liver, the hepatic metabolism of vitamin D<sub>3</sub> to 25(OH)D<sub>3</sub> is circumvented and consequently the

conversion from vitamin D<sub>3</sub> to 25(OH)D<sub>3</sub> would be negligible<sup>(59)</sup>. In patients with liver disease who had an impaired ability to synthesise 25(OH)D<sub>3</sub> from vitamin D<sub>3</sub><sup>(60)</sup>, the study of Sitrin and Bengoa<sup>(61)</sup> verified that 25(OH)D<sub>3</sub> could be absorbed more efficiently than vitamin D<sub>3</sub> after oral supplementation. Therefore, supplementation with 25(OH)D<sub>3</sub> is not only more efficient at increasing vitamin D status in generally healthy people, but may also have a specific role in tackling lower vitamin D status in patients who are suffering from liver diseases.

#### *Chronic effects and relative effectiveness of cholecalciferol and calcifediol treatments*

Regarding the expected higher biological effect of 25(OH)D<sub>3</sub> in raising serum or plasma 25(OH)D level after long-term administration, several studies have confirmed that oral consumption of 25(OH)D<sub>3</sub> is highly effective in raising serum or plasma 25(OH)D level (Table 4)<sup>(46–56)</sup>. However, the majority of the evidence in support of a higher impact of 25(OH)D<sub>3</sub> supplementation compared with vitamin D<sub>3</sub> on serum or plasma 25(OH)D<sub>3</sub> level is from only four studies<sup>(51,52,54,56)</sup> where both 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> treatments were included in the same study (Table 5). The study of Barger-Lux *et al.*<sup>(47)</sup> provided three different doses of vitamin D<sub>3</sub> (25, 250, 1250  $\mu\text{g}/\text{d}$ ) or 25(OH)D<sub>3</sub> (10, 20, 50  $\mu\text{g}/\text{d}$ ) to the participants for 8 and 4 weeks, respectively. However, the effects of 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> treatments were not directly comparable as the interventions were not at the same dose or treatment time. Thus, the study of Barger-Lux *et al.*<sup>(47)</sup> was excluded from the relative effectiveness analysis. In order to compare the relative effectiveness of 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> supplementation on raising serum or plasma 25(OH)D concentrations, a dose–response factor was calculated for each  $\mu\text{g}$  of orally consumed 25(OH)D<sub>3</sub> or vitamin D<sub>3</sub> in four studies<sup>(51,52,54,56)</sup>. The dose–response factors of 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> were calculated by using endpoint 25(OH)D concentration minus baseline 25(OH)D concentration, divided by the dose of the supplementation (dose–response factor =  $\Delta$  serum/plasma (mmol/l)/dose ( $\mu\text{g}$ )). Then, the relative



**Table 4.** Summary of study details and serum 25, hydroxyvitamin D (25(OH)D) concentration in long-term randomised controlled trials with calcifediol (25 hydroxyvitamin D<sub>3</sub> (25(OH)D<sub>3</sub>)) supplementation in adults (order by year)

References	Subjects characteristics (trial time during the year, subjects (sex), age, BMI)	25(OH)D <sub>3</sub> supplementation group					Control group (if available)				
		Duration	25(OH)D <sub>3</sub> treatment	n	Baseline 25(OH)D (nmol/l)	Endpoint 25(OH)D (nmol/l)	Duration	Vitamin D <sub>3</sub> treatment	n	Baseline 25(OH)D (nmol/l)	Endpoint 25(OH)D (nmol/l)
Hahn <i>et al.</i> <sup>(46)</sup>	Whole year, patients (women and men) with glucocorticoid-induced osteopenia 46 years, BMI (NA*)	18 months	40 µg/d + 500 mg calcium/d	9	39	205					
Barger-Lux <i>et al.</i> <sup>(47)</sup>	January–April, men 28 years, 26 kg/m <sup>2</sup>	4 weeks	10 µg/d	7	67	107	8 weeks	25 µg/d	13	67	96
		4 weeks	20 µg/d	6	67	143	8 weeks	250 µg/d	10	67	213
		4 weeks	50 µg/d	4	67	273	8 weeks	1250 µg/d	14	67	710
Jean <i>et al.</i> <sup>(48)</sup>	March–September, haemodialysis patients (women and men) 67 years, BMI (NA)	6 months	16 µg /d	149	30	126					
Cavalli <i>et al.</i> <sup>§(49)</sup>	April–July, postmenopausal women 65–75 years, 25 kg/m <sup>2</sup>	12 weeks	125 µg/week + 500 mg calcium/d	25	50	76					
		12 weeks	250 µg/month + 500 mg calcium/d	28	51	70					
		12 weeks	500 µg/month + 500 mg calcium/d	27	52	77					
Russo <i>et al.</i> <sup>(50)</sup>	January–April, women (7 premenopausal and 11 postmenopausal), 24–72 years, 24 kg/m <sup>2</sup>	16 weeks	500 µg/month	18	45	105 <sup>†</sup>					
Cashman <i>et al.</i> <sup>(51)</sup>	January–April, women and men, 57 years, 29 kg/m <sup>2</sup>	10 weeks	20 µg/d	12	38	135	10 weeks	20 µg/d	13	50	69
Jetter <i>et al.</i> <sup>‡§(52)</sup>	January–July, postmenopausal women 50–70 years, 18–29 kg/m <sup>2</sup>	16 weeks	20 µg/d	5	31	173	16 weeks	20 µg/d	5	35	77
Catalano <i>et al.</i> <sup>(54)</sup>	September–March, osteopenic and dyslipidaemic postmenopausal women 59 years, 27 kg/m <sup>2</sup>	24 weeks	140 µg once weekly	29	56	126	24 weeks	140 µg once weekly	28	51	61
Banon <i>et al.</i> <sup>(53)</sup>	Whole year, patients (women and men) had HIV-infected, 44 years, 15–44 kg/m <sup>2</sup>	Summer	400 µg once/month	123	37	86	Summer	NA	242	53	99
		Fall	400 µg once/month	123	37	69	Fall	NA	242	53	84
		Winter	400 µg once/month	123	37	45	Winter	NA	242	53	55
		Spring	400 µg once/month	123	37	57	Spring	NA	242	53	78
Ortego-Jurado <i>et al.</i> <sup>(55)</sup>	Whole year, patients (women and men) had autoimmune diseases, undergoing glucocorticoids therapy, 56 years, 28 kg/m <sup>2</sup>	Spring–summer	8-85 µg/d	49	NA	84	Spring–summer	20 µg/d	86	NA	71
		Fall–winter	8-85 µg/d	49	NA	89	Fall–winter	20 µg/d	86	NA	61
Navarro-Valverde <i>et al.</i> <sup>(56)</sup>	Whole year, postmenopausal osteoporotic women, 67 years, 26 kg/m <sup>2</sup>	6 months	20 µg/d	10	37	161	6 months	20 µg/d	10	41	80
		12 months	20 µg/d	10	37	188	12 months	20 µg/d	10	41	86
		6 months	266 µg once/week	10	38	214					
		12 months	266 µg once/week	10	38	233					
		6 months	266 µg once/2 weeks	10	40	165					
		12 months	266 µg once/2 weeks	10	40	211					

\* NA, not available.

† Estimated from graph.

‡ Same study of (Jetter *et al.*<sup>(52)</sup>) and (Bischoff-Ferrari *et al.*<sup>(62)</sup>).

§ Study has measured vitamin D status as 25(OH)D<sub>3</sub>.

**Table 5.** Summary of randomised controlled trials with both calcifediol (25 hydroxyvitamin D<sub>3</sub> (25(OH)D<sub>3</sub>)) and vitamin D<sub>3</sub> in adults to calculate the relative effectiveness of 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> supplementation in raising serum 25, hydroxyvitamin D (25(OH)D) level

References	Treatment (dose, duration)	Serum 25(OH)D raising (nmol/l) per 1 µg*	Relative effectiveness†
Cashman <i>et al.</i> <sup>(51)</sup>	20 µg 25(OH)D <sub>3</sub> /d × 10 weeks	4.82 <sup>a</sup>	4.99
	20 µg vitamin D <sub>3</sub> /d × 10 weeks	0.97 <sup>b</sup>	
Jetter <i>et al.</i> <sup>(52)</sup>	20 µg 25(OH)D <sub>3</sub> /d × 15 weeks	7.12 <sup>a</sup>	3.40
	20 µg vitamin D <sub>3</sub> /d × 15 weeks	2.51 <sup>b</sup>	
Catalano <i>et al.</i> <sup>(54)</sup>	140 µg 25(OH)D <sub>3</sub> /week × 24 weeks	0.50 <sup>a</sup>	7.14
	140 µg vitamin D <sub>3</sub> /week × 24 weeks	0.07 <sup>b</sup>	
Navarro-Valverde <i>et al.</i> <sup>(56)</sup>	20 µg 25(OH)D <sub>3</sub> /d × 6 months	6.19 <sup>a</sup>	3.13
	20 µg vitamin D <sub>3</sub> /d × 6 months	1.98 <sup>b</sup>	
	20 µg 25(OH)D <sub>3</sub> /d × 12 months	7.54 <sup>a</sup>	3.29
	20 µg vitamin D <sub>3</sub> /d × 12 months	2.29 <sup>b</sup>	

\* Dose–response factor = Δ serum/plasma (nmol/l)/dose (µg).

† Relative effectiveness = a/b within same study.

effectiveness of 25(OH)D<sub>3</sub> to vitamin D<sub>3</sub> was calculated by dividing the dose–response factor of 25(OH)D<sub>3</sub> by that of vitamin D<sub>3</sub>.

The highest relative effectiveness was found in the study by Catalano *et al.*<sup>(54)</sup>. Weekly treatment of 140 µg 25(OH)D<sub>3</sub> or 140 µg vitamin D<sub>3</sub> supplements was provided to osteopenic and dyslipidaemic postmenopausal women for 24 weeks. Supplementation with 25(OH)D<sub>3</sub> raised serum 25(OH)D from a baseline of 56–126 nmol/l, while vitamin D<sub>3</sub> treatment increased serum 25(OH)D to a lower extent, from baseline 51 to 61 nmol/l. Thus, the relative effectiveness factor derived from this study was 7.14, i.e. dietary 25(OH)D<sub>3</sub> was 7.14 times more effective at increasing serum 25(OH)D than dietary vitamin D<sub>3</sub>.

Vitamin D dietary recommendations are generally between 10 and 20 µg/d<sup>(10)</sup>, yet, there are few studies which have compared the effectiveness of dietary 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> using doses of 20 µg in their treatments. Cashman *et al.*<sup>(51)</sup> provided daily supplements of 20 µg vitamin D<sub>3</sub> or 20 µg 25(OH)D<sub>3</sub> to adult men and women with a mean age of 57 years and with baseline serum 25(OH)D of 28.9 nmol/l during winter. After 10 weeks of supplementation, the subjects' serum 25(OH)D increased to 135 and 69 nmol/l for the 25(OH)D<sub>3</sub> and vitamin D<sub>3</sub> treatments, respectively. A relative effectiveness factor of 4.99 was calculated representing the relative effectiveness of each µg of dietary 25(OH)D<sub>3</sub> relative to dietary vitamin D<sub>3</sub> for raising serum 25(OH)D concentration. However, lower relative effectiveness factors were achieved in other studies using the same dose of 20 µg vitamin D<sub>3</sub> and 25(OH)D<sub>3</sub>. Jetter *et al.* supplemented healthy postmenopausal women with 20 µg 25(OH)D<sub>3</sub> or 20 µg vitamin D<sub>3</sub> for 16 weeks during the winter<sup>(52)</sup>. They found that for the 25(OH)D<sub>3</sub> treatment, plasma 25(OH)D<sub>3</sub> increased to 173 nmol/l from a baseline of 31 nmol/l, whereas for the vitamin D<sub>3</sub> treatment, plasma 25(OH)D<sub>3</sub> increased to 77 nmol/l from a baseline level of 35 nmol/l. The relative effectiveness factor of each µg of 25(OH)D<sub>3</sub> was 3.40 compared with vitamin D<sub>3</sub> in raising plasma 25(OH)D<sub>3</sub> level. A similar low relative effectiveness factor was found in another study where post-menopausal osteoporotic women were given either 20 µg vitamin D<sub>3</sub> or 20 µg

25(OH)D<sub>3</sub> over 6 or 12 months<sup>(56)</sup>. The serum concentration of 25(OH)D for the 25(OH)D<sub>3</sub> treatment reached 161 and 188 nmol/l from a baseline of 37 nmol/l after 6 or 12 months administration, respectively, while the comparable values for the vitamin D<sub>3</sub> treatment were an increase to 80 and 86 nmol/l from a baseline of 41 nmol/l. So the relative effectiveness factor of 25(OH)D<sub>3</sub> relative to vitamin D<sub>3</sub> treatment at 6 and 12 months were 3.13 or 3.29, respectively.

In summary, of the studies reviewed, the relative effectiveness of 25(OH)D<sub>3</sub> to vitamin D<sub>3</sub> for raising vitamin D status (Table 5), ranged from 3.13 to 7.14. Previous studies have demonstrated that the season may have influences on vitamin D status<sup>(13,14)</sup>. There were two studies conducted during the winter which may have minimised any confounding influence of cutaneous vitamin D synthesis from UV radiation<sup>(47,51)</sup>. Other studies have longer intervention periods of 6 months or more, which could not have avoided some cutaneous synthesis. Furthermore, baseline status may be another factor that influences the relative effectiveness factor. The study of Catalano *et al.* had the highest factor of 7.14 in the present review, and the baseline concentration of 25(OH)D of the study participants was higher (>50 nmol/l) than the others<sup>(54)</sup>. Therefore, the different relative effectiveness seen in different studies may be due to the different characteristics or genotypes of the subjects, or different study designs.

Overall, evidence suggests that dietary 25(OH)D<sub>3</sub> can more effectively increase serum 25(OH)D concentrations than vitamin D<sub>3</sub> and may also be absorbed faster reaching a serum or plasma 25(OH)D plateau earlier than vitamin D<sub>3</sub> supplementation. Furthermore, supplementation with 25(OH)D<sub>3</sub> may also have more benefits to human health compared with vitamin D<sub>3</sub> in a general healthy population. Bischoff-Ferrari *et al.* reported that 20 µg 25(OH)D<sub>3</sub> supplementation over 4 months led to a 5.7 mmHg decrease in systolic blood pressure and improvements in several markers of innate immunity in healthy postmenopausal women<sup>(62)</sup>.

For patients with different diseases and receiving long-term medication, studies<sup>(63–65)</sup> showed that several drugs (e.g. antiepileptic agents, glucocorticoids, antiretroviral



or anti-oestrogen drugs) interfered with vitamin D metabolism, which resulted in patients being more likely to have low vitamin D status. Thus, it is not only important to increase vitamin D status in the generally healthy population but also in patients with specific illnesses and receiving certain medication. Therefore, the studies using 25(OH)D<sub>3</sub> treatments in patients were also summarised in Table 4<sup>(46,48,53–56)</sup>, and those studies consistently reported that chronic 25(OH)D<sub>3</sub> supplementation effectively increased serum 25(OH)D concentrations. For example, Ortego-Jurado *et al.* showed a lower daily dose of 8.85 µg 25(OH)D<sub>3</sub> to be more effective than a 20 µg dose of vitamin D<sub>3</sub> for increasing vitamin D status in patients with autoimmune disease who were treated with a low dose of glucocorticoids throughout the year<sup>(55)</sup>. Similarly, the study of Banon *et al.* showed that a monthly dose of 400 µg 25(OH)D<sub>3</sub> was safe and effective at improving vitamin D status of HIV-infected patients throughout the year<sup>(53)</sup>.

Furthermore, supplementation with 25(OH)D<sub>3</sub> may have additional benefits on patients' health. Previously, 25(OH)D<sub>3</sub> was recommended for patients with kidney disease since 25(OH)D<sub>3</sub> has a direct action on bone metabolism<sup>(66)</sup>. Hahn *et al.* provided a daily 40 µg 25(OH)D<sub>3</sub> and 500 mg calcium supplement to patients who had glucocorticoid-induced osteopenia for 18 months<sup>(46)</sup>. The treatment markedly increased vitamin D status from 39 to 205 nmol/l. In addition, this study showed that the 25(OH)D<sub>3</sub> treatment improved mineral and bone metabolism. Jean *et al.* also offered haemodialysis patients who suffered from vitamin D deficiency with a daily dose of 16 µg 25(OH)D<sub>3</sub> for 6 months; vitamin D status reached 126 nmol/l from 30 nmol/l, at the same time 25(OH)D<sub>3</sub> supplementation corrected the excess bone turnover<sup>(48)</sup>. Similarly, a study by Catalano *et al.*<sup>(54)</sup> provided 140 µg 25(OH)D<sub>3</sub> supplements for 24 weeks to osteopenic and dyslipidaemic postmenopausal women, and results showed that 25(OH)D<sub>3</sub> improved plasma lipid levels (increased HDL-cholesterol ( $P = 0.02$ ) and decreased LDL-cholesterol ( $P = 0.02$ )) in osteopenic and dyslipidaemic postmenopausal women when added to an ongoing atorvastatin treatment.

As an alternative to vitamin D-enriched foods, vitamin D fortification of foods may also be an option for tackling vitamin D deficiency throughout the world. In general, fortification of foods refers to mandatory and voluntary fortification. The contribution of vitamin D-fortified foods to vitamin D intake by the public varies considerably between countries as there are different food standard policies<sup>(10)</sup>, and in practice, vitamin D<sub>2</sub> or vitamin D<sub>3</sub> are used for fortification. Evidence from one previous meta-analysis of RCT showed that vitamin D<sub>3</sub> supplementation is more effective at raising vitamin D status than vitamin D<sub>2</sub><sup>(67)</sup>. However, a further comprehensive systematic review and meta-analysis of thirty-three RCT<sup>(68)</sup> showed that the effect of vitamin D<sub>3</sub> supplement on serum 25(OH)D<sub>3</sub> response was limited by the supplemental dose, duration, age of subjects and baseline level. In addition, the meta-analysis showed a greater serum or plasma 25(OH)D increase when the intervention study used a dose of 20 µg/d vitamin D<sub>3</sub> or

even higher, with subjects aged >80 years and an administration period of at least 6–12 months or subjects had lower baseline 25(OH)D status (<50 nmol/l) than subjects aged <80 years, administration period <6 months or subjects had higher baseline 25(OH)D status (≥50 nmol/l)<sup>(68)</sup>. Therefore, better strategies are needed to raise vitamin D status of the public throughout life, and 25(OH)D<sub>3</sub>-fortified foods warrant further research.

## Conclusions

Vitamin D insufficiency has become a world problem, especially where sunlight exposure is limited by geographic reasons (latitude), personal characteristics (skin pigmentation, ageing) or behaviour (sunscreen use, cultural reasons). However, there are a few natural foods rich in vitamin D. Thus, vitamin D-enriched foods produced through a food chain approach such as feeding animals vitamin D supplements or vitamin D-fortified foods are needed to guarantee an adequate dietary intake of vitamin D by the general population.

The present review summarised the available and limited number of RCT investigating the effect of 25(OH)D<sub>3</sub> supplementation on serum or plasma 25(OH)D concentration. We concluded that it is difficult to get consensus on the effectiveness of 25(OH)D<sub>3</sub> supplementation relative to vitamin D<sub>3</sub> for raising vitamin D status, due to various influencing factors such as different person characteristics (age, BMI), baseline vitamin D status and time of the year. However, it is unquestionable that 25(OH)D<sub>3</sub> supplementation is more efficient at raising serum 25(OH)D concentrations and also appears to be absorbed faster by than the same dose of vitamin D<sub>3</sub>. Second, by reviewing available evidence on vitamin D-enriched eggs, fish or milk, it is practical and possible to increase the vitamin D content of eggs, fish or milk by addition of vitamin D supplements to the diet of poultry, fish or dairy cows. However, the limitations of adding vitamin D to animal feed should be considered in future enrichment studies. Furthermore, there are a few RCT investigating the impact of these vitamin D-enriched foods on improving vitamin D status. Therefore, 25(OH)D<sub>3</sub>-enriched or fortified foods should be further explored in the future, and additional RCT should be conducted to investigate the effect of 25(OH)D<sub>3</sub>-enriched or fortified foods on vitamin D status of the general population and patients with long-term health conditions.

## Financial Support

This review received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. J. G. was supported by the Barham Benevolent Foundation studentship.

## Conflicts of Interest

None.



### Authorship

J. G. conceived and wrote the manuscript. All authors critically reviewed and approved the final version of the manuscript.

### References

- Borradale D & Kimlin M (2009) Vitamin D in health and disease: an insight into traditional functions and new roles for the 'sunshine vitamin'. *Nutr Res Rev* **22**, 118–136.
- Holick MF, Binkley NC, Bischoff-Ferrari HA *et al.* (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* **96**, 1911–1930.
- Robinson PD, Hogler W, Craig ME *et al.* (2006) The re-emerging burden of rickets: a decade of experience from Sydney. *Arch Dis Child* **91**, 564–568.
- Ward LM, Gabooury I, Ladhani M *et al.* (2007) Vitamin D-deficiency rickets among children in Canada. *CMAJ* **177**, 161–166.
- Prentice A (2013) Nutritional rickets around the world. *J Steroid Biochem Mol Biol* **136**, 201–206.
- Holick MF & Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. *Am J Clin Nutr* **87**, 1080S–1086S.
- Scientific Advisory Committee on Nutrition (2016) <https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report> (accessed August 17).
- Forrest KY & Stuhldreher WL (2011) Prevalence and correlates of vitamin D deficiency in US adults. *Nutr Res* **31**, 48–54.
- Hilger J, Friedel A, Herr R *et al.* (2014) A systematic review of vitamin D status in populations worldwide. *Br J Nutr* **111**, 23–45.
- Cashman KD & Kiely M (2016) Tackling inadequate vitamin D intakes within the population: fortification of dairy products with vitamin D may not be enough. *Endocrine* **51**, 38–46.
- Nowson CA, McGrath JJ, Ebeling PR *et al.* (2012) Vitamin D and health in adults in Australia and New Zealand: a position statement. *Med J Aust* **196**, 686–687.
- Holick MF (1995) Environmental-factors that influence the cutaneous production of vitamin-D. *Am J Clin Nutr* **61**, 638s–645s.
- Schmid A & Walther B (2013) Natural vitamin D content in animal products. *Adv Nutr* **4**, 453–462.
- O'Mahony L, Stepien M, Gibney MJ *et al.* (2011) The potential role of vitamin D enhanced foods in improving vitamin D status. *Nutrients* **3**, 1023–1041.
- Holick MF, MacLaughlin JA, Clark MB *et al.* (1980) Photosynthesis of previtamin D<sub>3</sub> in human skin and the physiologic consequences. *Science* **210**, 203–205.
- Haddad JG, Matsuoka LY, Hollis BW *et al.* (1993) Human plasma transport of vitamin D after its endogenous synthesis. *J Clin Invest* **91**, 2552–2555.
- Dueland S, Pedersen JI, Helgerud P *et al.* (1983) Absorption, distribution, and transport of vitamin D<sub>3</sub> and 25-hydroxyvitamin D<sub>3</sub> in rat. *Am J Physiol* **245**, 5 Pt1, E463–E467.
- Jones G, Strugnell SA & DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. *Physiol News* **78**, 1193–1231.
- Exler J, Phillips KM, Patterson KY *et al.* (2013) Cholesterol and vitamin D content of eggs in the US retail market. *J Food Comp Anal* **29**, 110–116.
- Guo J, Kliem KE, Lovegrove JA *et al.* (2017) Effect of production system, supermarket and purchase date on the vitamin D content of eggs at retail. *Food Chem* **221**, 1021–1025.
- Lu Z, Chen TC, Zhang A *et al.* (2007) An evaluation of the vitamin D<sub>3</sub> content in fish: Is the vitamin D content adequate to satisfy the dietary requirement for vitamin D? *J Steroid Biochem Mol Biol* **103**, 642–644.
- Mattila P, Piironen V, Uusi-Rauva E *et al.* (1995) Cholecalciferol and 25-hydroxycholecalciferol contents in fish and fish products. *J Food Comp Anal* **8**, 232–243.
- Bilodeau L, Dufresne G, Deeks J *et al.* (2011) Determination of vitamin D<sub>3</sub> and 25-hydroxyvitamin D<sub>3</sub> in foodstuffs by HPLC UV-DAD and LC-MS/MS. *J Food Comp Anal* **24**, 441–448.
- Bates B, Lennox A, Bates C *et al.* (2014) *National Diet and Nutrition Survey (2008/2009–2011/2012)*. London: Public Health England Publications.
- Kuhn J, Schutkowski A, Kluge H *et al.* (2014) Free-range farming: a natural alternative to produce vitamin D-enriched eggs. *Nutrition* **30**, 481–484.
- Mattila P, Lehtikoinen K, Kiiskinen T *et al.* (1999) Cholecalciferol and 25-hydroxycholecalciferol content of chicken egg yolk as affected by the cholecalciferol content of feed. *J Agric Food Chem* **47**, 4089–4092.
- Mattila P, Lehtikoinen K, Kiiskinen T *et al.* (2003) Effect of cholecalciferol-enriched hen feed on egg quality. *J Agric Food Chem* **51**, 283–287.
- Mattila P, Valaja J, Rossow L *et al.* (2004) Effect of vitamin D<sub>2</sub>- and D<sub>3</sub>-enriched diets on egg vitamin D content, production, and bird condition during an entire production period. *Poult Sci* **83**, 433–440.
- Mattila P, Vakonen E & Valaja J (2011) Effect of different vitamin D supplementations in poultry feed on vitamin D content of eggs and chicken meat. *J Agric Food Chem* **59**, 8298–8303.
- Yao LX, Wang T, Persia M *et al.* (2013) Effects of vitamin D<sub>3</sub>-enriched diet on egg yolk vitamin D<sub>3</sub> content and yolk quality. *J Food Sci* **78**, C178–C183.
- Browning LC & Cowieson AJ (2014) Vitamin D fortification of eggs for human health. *J Sci Food Agric* **94**, 1389–1396.
- Duffy SK, Rajauria G, Clarke LC *et al.* (2017) The potential of cholecalciferol and 25-hydroxyvitamin D<sub>3</sub> enriched diets in laying hens, to improve egg vitamin D content and antioxidant availability. *Innov Food Sci Emerg Technol* <https://doi.org/10.1016/j.ifset.2017.07.007>.
- EFSA FEEDAP Panel (EFSA Panel on Additives and Products or Substances used in Animal Feed) (2012) Scientific Opinion on the safety and efficacy of vitamin D<sub>3</sub> (cholecalciferol) as a feed additive for chickens for fattening, turkeys, other poultry, pigs, piglets (suckling), calves for rearing, calves for fattening, bovines, ovines, equines, fish and other animal species or categories, based on a dossier submitted by DSM. *EFSA J* **10**, 2968, 26 pp.
- The Commission of the European Communities (2017) Commission Implementing Regulation (EC) No 2017/1492. The authorisation of cholecalciferol as a feed additive for all animal species. *Off J Eur Union* **L216/19**.
- Horvli O, LIE O & Aksnes L (1998) Tissue distribution of vitamin D<sub>3</sub> in Atlantic salmon *Salmo salar*: effect of dietary level. *Aquacul Nutr* **4**, 127–131.
- Vielma J, Lall SP, Koskela J *et al.* (1998) Effects of dietary phytase and cholecalciferol on phosphorus bioavailability in rainbow trout (*Oncorhynchus mykiss*). *Aquaculture* **163**, 309–323.
- Mattila P, Piironen V, Hakkarainen T *et al.* (1999) Possibilities to raise vitamin D content of rainbow trout

- (*Oncorhynchus mykiss*) by elevated feed cholecalciferol contents. *J Sci Food Agric* **79**, 195–198.
38. Graff IE, Hoie S, Totland GK *et al.* (2002) Three different levels of dietary vitamin D-3 fed to first-feeding fry of Atlantic salmon (*Salmo salar* L.): effect on growth, mortality, calcium content and bone formation. *Aquac Nutr* **8**, 103–111.
  39. Hollis BW, Roos BA, Draper HH *et al.* (1981) Vitamin D and its metabolites in human and bovine milk. *J Nutr* **111**, 1240–1248.
  40. Reeve LE, Jorgensen NA & Deluca HF (1982) Vitamin-D compounds in cows milk. *J Nutr* **112**, 667–672.
  41. Mcdermott CM, Beitz DC, Littledike ET *et al.* (1985) Effects of dietary vitamin-D<sub>3</sub> on concentrations of vitamin-D and its metabolites in blood-plasma and milk of dairy-cows. *J Dairy Sci* **68**, 1959–1967.
  42. Weiss WP, Azem E, Steinberg W *et al.* (2015) Effect of feeding 25-hydroxyvitamin D<sub>3</sub> with a negative cation-anion difference diet on calcium and vitamin D status of periparturient cows and their calves. *J Dairy Sci* **98**, 5588–5600.
  43. Hayes A, Duffy S, O'Grady M *et al.* (2016) Vitamin D-enhanced eggs are protective of wintertime serum 25-hydroxyvitamin D in a randomized controlled trial of adults. *Am J Clin Nutr* **104**, 629–637.
  44. Jakobsen J (2007) Bioavailability and bioactivity of vitamin D<sub>3</sub> active compounds – Which potency should be used for 25-hydroxyvitamin D<sub>3</sub>? *Int Congr Ser* **1297**, 133–142.
  45. McCance RA & Widdowson EM (2015) *Composition of Foods*, 7th ed. Cambridge: The Royal Society of Chemistry.
  46. Hahn TJ, Halstead LR, Teitelbaum SL *et al.* (1979) Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. *J Clin Invest* **64**, 655–665.
  47. Barger-Lux MJ, Heaney RP, Dowell S *et al.* (1998) Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. *Osteoporos Int* **8**, 222–230.
  48. Jean G, Terrat JC, Vanel T *et al.* (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. *Nephrol Dial Transplant* **23**, 3670–3676.
  49. Cavalli L, Cavalli T, Marcucci G *et al.* (2009) Biological effects of various regimes of 25-hydroxyvitamin D<sub>3</sub> (calcidiol) administration on bone mineral metabolism in postmenopausal women. *Clin Cases Miner Bone Metab* **6**, 169–173.
  50. Russo S, Carlucci L, Cipriani C *et al.* (2011) Metabolic changes following 500 mug monthly administration of calcidiol: a study in normal females. *Calcif Tissue Int* **89**, 252–257.
  51. Cashman KD, Seamans KM, Lucey AJ *et al.* (2012) Relative effectiveness of oral 25-hydroxyvitamin D<sub>3</sub> and vitamin D<sub>3</sub> in raising wintertime serum 25-hydroxyvitamin D in older adults. *Am J Clin Nutr* **95**, 1350–1356.
  52. Jetter A, Egli A, Dawson-Hughes B *et al.* (2014) Pharmacokinetics of oral vitamin D(3) and calcifediol. *Bone* **59**, 14–19.
  53. Banon S, Rosillo M, Gomez A *et al.* (2015) Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients. *Endocrine* **49**, 528–537.
  54. Catalano A, Morabito N, Basile G *et al.* (2015) Calcifediol improves lipid profile in osteopenic atorvastatin-treated postmenopausal women. *Eur J Clin Invest* **45**, 144–149.
  55. Ortega-Jurado M, Callejas-Rubio JL, Rios-Fernandez RR *et al.* (2015) Oral calcidiol is more effective than cholecalciferol supplementation to reach adequate 25(OH)D levels in patients with autoimmune diseases chronically treated with low doses of glucocorticoids: a 'Real-Life' study. *J Osteoporos* <http://dx.doi.org/10.1155/2015/729451>.
  56. Navarro-Valverde C, Sosa-Henriquez M, Alhambra-Exposito MR *et al.* (2016) Vitamin D3 and calcidiol are not equipotent. *J Steroid Biochem Mol Biol* **164**, 205–208.
  57. Haddad JG & Rojanasathit S (1976) Acute administration of 25-hydroxycholecalciferol in man. *J Clin Endocrinol Metab* **42**, 284–290.
  58. Cianferotti L, Cricelli C, Kanis JA *et al.* (2015) The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). *Endocrine* **50**, 12–26.
  59. Heaney RP, Armas LA, Shary JR *et al.* (2008) 25-hydroxylation of vitamin D<sub>3</sub>: relation to circulating vitamin D<sub>3</sub> under various input conditions. *Am J Clin Nutr* **87**, 1738–1742.
  60. Nair S (2010) Vitamin D deficiency and liver disease. *Gastroenterol Hepatol (NY)* **6**, 491–493.
  61. Sitrin MD & Bengoa JM (1987) Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease. *Am J Clin Nutr* **46**, 1011–1015.
  62. Bischoff-Ferrari HA, Dawson-Hughes B, Stocklin E *et al.* (2012) Oral supplementation with 25(OH)D<sub>3</sub> versus vitamin D<sub>3</sub>: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. *J Bone Miner Res* **27**, 160–169.
  63. Mehrotra R, Kermah D, Budoff M *et al.* (2008) Hypovitaminosis D in chronic kidney disease. *Clin J Am Soc Nephrol* **3**, 1144–1151.
  64. Grober U & Kisters K (2012) Influence of drugs on vitamin D and calcium metabolism. *Dermatoendocrinology* **4**, 158–166.
  65. Griz L, Bandeira F, Diniz ET *et al.* (2013) Prevalence of vitamin D deficiency is higher in patients with Paget's disease of bone compared with age-matched controls. *Arq Bras Endocrinol Metabol* **57**, 509–512.
  66. Torregrosa JV, Bover J, Cannata AJ *et al.* (2011) Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.-M.B.D.). *Nefrologia* **31**, Suppl. 1, 3–32.
  67. Tripkovic L, Lambert H, Hart K *et al.* (2012) Comparison of vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. *Am J Clin Nutr* **95**, 1357–1364.
  68. Shab-Bidar S, Bours S, Geusens PP *et al.* (2014) Serum 25 (OH)D response to vitamin D<sub>3</sub> supplementation: a meta-regression analysis. *Nutrition* **30**, 975–985.

